Nicotinamide riboside

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Nicotinamide riboside
DrugBank Accession Number
DB14933
Background

Nicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 255.2472
Monoisotopic: 255.0980966
Chemical Formula
C11H15N2O5
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
0I8H2M0L7N
CAS number
1341-23-7
InChI Key
JLEBZPBDRKPWTD-TURQNECASA-O
InChI
InChI=1S/C11H14N2O5/c12-10(17)6-2-1-3-13(4-6)11-9(16)8(15)7(5-14)18-11/h1-4,7-9,11,14-16H,5H2,(H-,12,17)/p+1/t7-,8-,9-,11-/m1/s1
IUPAC Name
3-carbamoyl-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1lambda5-pyridin-1-ylium
SMILES
NC(=O)C1=C[N+](=CC=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

References

General References
Not Available
Human Metabolome Database
HMDB0000855
KEGG Compound
C03150
ChemSpider
388956
ChEBI
15927
ChEMBL
CHEMBL438497
ZINC
ZINC000004096036
PDBe Ligand
NNR
Wikipedia
Nicotinamide_riboside
PDB Entries
2qt0 / 2qt1 / 4qtn / 6gye

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Sequelae of; Infection / Symptoms, Cognitive1
4RecruitingTreatmentHealthy Subjects (HS)1
3RecruitingTreatmentPeripheral Arterial Disease (PAD)1
2Not Yet RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF)1
2RecruitingPreventionAcute Kidney Injury (AKI)1
2RecruitingPreventionSmall Fibre Neuropathy1
2RecruitingTreatmentAcute Kidney Injury (AKI) / Coronavirus Disease 2019 (COVID‑19)1
2RecruitingTreatmentAging / High Blood Pressure (Hypertension)1
2RecruitingTreatmentBlood Pressures / Kidney Diseases / Stress Oxidative / Vascular Diseases1
2RecruitingTreatmentChemotherapy Induced Peripheral Neuropathy (CIPN)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.45 mg/mLALOGPS
logP-2.3ALOGPS
logP-6.1ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)11.39ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area116.89 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity60.83 m3·mol-1ChemAxon
Polarizability24.83 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-e25d1beb47cb1fe9e4cb
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-002b-3090000000-03687e9ef697eda1d6c8
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052g-9300000000-2755bde4df843d2227f2
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0090000000-809be1146b2a2c8d96a7
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-1390000000-2fc72cf0619f182e044f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0k96-9300000000-4d5b96b192f3484b1b8a

Drug created on May 20, 2019 14:36 / Updated on June 12, 2020 16:53